Literature DB >> 27467942

CD73-adenosine reduces immune responses and survival in ovarian cancer patients.

Pierre-Olivier Gaudreau1, Bertrand Allard1, Martin Turcotte1, John Stagg1.   

Abstract

Multiple non-redundant immunosuppressive pathways are active within the microenvironment of cancers to avoid tumor eradication by the immune system. Our results demonstrate that the CD73-adenosine pathway is a major immunosuppressive mechanism co-opted by ovarian tumors to escape antitumor immunity. In ovarian cancer patients, high CD73 expression correlates with poor outcome and impaired CD8(+) T cell immunosurveillance.

Entities:  

Keywords:  A2A; adenosine; CD39; CD73; immune checkpoint; immunotherapy

Year:  2016        PMID： 27467942      PMCID： PMC4910753          DOI： 10.1080/2162402X.2015.1127496

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.

Authors:  Deepak Mittal; Arabella Young; Kimberley Stannard; Michelle Yong; Michele W L Teng; Bertrand Allard; John Stagg; Mark J Smyth
Journal:  Cancer Res       Date:  2014-07-01       Impact factor: 12.701

Review 2.  Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.

Authors:  Bertrand Allard; Martin Turcotte; John Stagg
Journal:  Expert Opin Ther Targets       Date:  2014-05-06       Impact factor: 6.902

3.  CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.

Authors:  Dachuan Jin; Jie Fan; Long Wang; Linda F Thompson; Aijie Liu; Benjamin J Daniel; Tahiro Shin; Tyler J Curiel; Bin Zhang
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

4.  CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.

Authors:  John Stagg; Upulie Divisekera; Helene Duret; Tim Sparwasser; Michele W L Teng; Phillip K Darcy; Mark J Smyth
Journal:  Cancer Res       Date:  2011-02-03       Impact factor: 12.701

5.  Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.

Authors:  Paul A Beavis; Nicole Milenkovski; Melissa A Henderson; Liza B John; Bertrand Allard; Sherene Loi; Michael H Kershaw; John Stagg; Phillip K Darcy
Journal:  Cancer Immunol Res       Date:  2015-02-11       Impact factor: 11.151

6.  Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.

Authors:  John Stagg; Upulie Divisekera; Nicole McLaughlin; Janelle Sharkey; Sandra Pommey; Delphine Denoyer; Karen M Dwyer; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

Review 7.  CD39 and CD73 in immunity and inflammation.

Authors:  Luca Antonioli; Pál Pacher; E Sylvester Vizi; György Haskó
Journal:  Trends Mol Med       Date:  2013-04-17       Impact factor: 11.951

8.  CD73 is associated with poor prognosis in high-grade serous ovarian cancer.

Authors:  Martin Turcotte; Kathleen Spring; Sandra Pommey; Guillaume Chouinard; Isabelle Cousineau; Joshy George; Gregory M Chen; Deena M A Gendoo; Benjamin Haibe-Kains; Thomas Karn; Kurosh Rahimi; Cécile Le Page; Diane Provencher; Anne-Marie Mes-Masson; John Stagg
Journal:  Cancer Res       Date:  2015-09-11       Impact factor: 12.701

9.  Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.

Authors:  Bertrand Allard; Sandra Pommey; Mark J Smyth; John Stagg
Journal:  Clin Cancer Res       Date:  2013-08-27       Impact factor: 12.531

10.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240
  10 in total
  14 in total

Review 1.  Natural Killer Cells: the Missing Link in Effective Treatment for High-Grade Serous Ovarian Carcinoma.

Authors:  Morgan Pugh-Toole; Anna P Nicolela; Sarah Nersesian; Brendan M Leung; Jeanette E Boudreau
Journal:  Curr Treat Options Oncol       Date:  2022-02-22

Review 2.  ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain.

Authors:  Gennady G Yegutkin; Detlev Boison
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

Review 3.  Autocrine and paracrine purinergic signaling in the most lethal types of cancer.

Authors:  M Reyna-Jeldes; M Díaz-Muñoz; J A Madariaga; C Coddou; F G Vázquez-Cuevas
Journal:  Purinergic Signal       Date:  2021-05-12       Impact factor: 3.765

4.  CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy.

Authors:  Lauren Giuffrida; Kevin Sek; Melissa A Henderson; Junyun Lai; Amanda X Y Chen; Deborah Meyran; Kirsten L Todd; Emma V Petley; Sherly Mardiana; Christina Mølck; Gregory D Stewart; Benjamin J Solomon; Ian A Parish; Paul J Neeson; Simon J Harrison; Lev M Kats; Imran G House; Phillip K Darcy; Paul A Beavis
Journal:  Nat Commun       Date:  2021-05-28       Impact factor: 14.919

5.  Prognositic value of CD73-adenosinergic pathway in solid tumor: A meta-analysis and systematic review.

Authors:  Rong Wang; Yingying Zhang; Xia Lin; Yalin Gao; Ying Zhu
Journal:  Oncotarget       Date:  2017-04-06

6.  KLRG1 restricts memory T cell antitumor immunity.

Authors:  Lei Li; Shanshan Wan; Kaixiong Tao; Guobin Wang; Ende Zhao
Journal:  Oncotarget       Date:  2016-09-20

Review 7.  Targeting adenosine for cancer immunotherapy.

Authors:  Robert D Leone; Leisha A Emens
Journal:  J Immunother Cancer       Date:  2018-06-18       Impact factor: 13.751

Review 8.  FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy.

Authors:  Xin Chen; Xiaomin Song; Kang Li; Tong Zhang
Journal:  Front Immunol       Date:  2019-02-26       Impact factor: 7.561

9.  Downregulation of CD73 associates with T cell exhaustion in AML patients.

Authors:  Yaxian Kong; Bei Jia; Chenchen Zhao; David F Claxton; Arati Sharma; Charyguly Annageldiyev; Joseph S Fotos; Hui Zeng; Robert F Paulson; K Sandeep Prabhu; Hong Zheng
Journal:  J Hematol Oncol       Date:  2019-04-24       Impact factor: 17.388

10.  Increased frequency of TIGIT+CD73-CD8+ T cells with a TOX+ TCF-1low profile in patients with newly diagnosed and relapsed AML.

Authors:  F Brauneck; F Haag; R Woost; N Wildner; E Tolosa; A Rissiek; G Vohwinkel; J Wellbrock; C Bokemeyer; J Schulze Zur Wiesch; C Ackermann; W Fiedler
Journal:  Oncoimmunology       Date:  2021-06-21       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.